MA32006B1 - Inhibiteurs de polymerase virale - Google Patents

Inhibiteurs de polymerase virale

Info

Publication number
MA32006B1
MA32006B1 MA33004A MA33004A MA32006B1 MA 32006 B1 MA32006 B1 MA 32006B1 MA 33004 A MA33004 A MA 33004A MA 33004 A MA33004 A MA 33004A MA 32006 B1 MA32006 B1 MA 32006B1
Authority
MA
Morocco
Prior art keywords
polymerase inhibitors
viral polymerase
inhibitors
viral
hepatitis
Prior art date
Application number
MA33004A
Other languages
Arabic (ar)
English (en)
Inventor
Pierre L Beaulieu
Pasquale Forgione
Alexandre Gagnon
Cedrickx Godbout
Marc-André Joly
Montse Llinas-Brunet
Julie Naud
Martin Poirier
Jean Rancourt
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA32006B1 publication Critical patent/MA32006B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Les composés représentés par la formule i : dans laquelle x, r2, r3, r3a, r3b, r5 et r6 sont définis présentement, sont utiles comme inhibiteurs de la polymérase ns5b du virus de l'hépatite c.
MA33004A 2007-12-19 2010-07-09 Inhibiteurs de polymerase virale MA32006B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1512307P 2007-12-19 2007-12-19
PCT/CA2008/002107 WO2009076747A1 (fr) 2007-12-19 2008-12-03 Inhibiteurs de polymérase virale

Publications (1)

Publication Number Publication Date
MA32006B1 true MA32006B1 (fr) 2011-01-03

Family

ID=40795136

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33004A MA32006B1 (fr) 2007-12-19 2010-07-09 Inhibiteurs de polymerase virale

Country Status (23)

Country Link
US (3) US8476257B2 (fr)
EP (1) EP2234977A4 (fr)
JP (1) JP5623289B2 (fr)
KR (1) KR20100098534A (fr)
CN (2) CN101903351B (fr)
AR (1) AR069832A1 (fr)
AU (1) AU2008338273B2 (fr)
BR (1) BRPI0821342A2 (fr)
CA (1) CA2708324C (fr)
CL (1) CL2008003819A1 (fr)
CO (1) CO6231024A2 (fr)
EA (1) EA201000948A1 (fr)
EC (1) ECSP10010260A (fr)
IL (1) IL205064A0 (fr)
MA (1) MA32006B1 (fr)
MX (1) MX2010006313A (fr)
NZ (1) NZ585370A (fr)
PE (2) PE20130157A1 (fr)
TN (1) TN2010000291A1 (fr)
TW (1) TW200927106A (fr)
UY (1) UY31538A1 (fr)
WO (1) WO2009076747A1 (fr)
ZA (1) ZA201002638B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2009018656A1 (fr) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Inhibiteurs de polymerase virale
CA2693997C (fr) * 2007-08-03 2013-01-15 Pierre L. Beaulieu Inhibiteurs de polymerase virale
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
US8410091B1 (en) 2009-09-11 2013-04-02 Boehringer Ingelheim International Gmbh Process for preparation of substituted 2-amino-5-(5-(heterocyclemethyl)pyridin-2-yloxy)benzoic acid
WO2012150221A2 (fr) 2011-05-04 2012-11-08 Bayer Cropscience Ag Nouveaux esters d'alcools benzyliques halogénés de l'acide cyclopropancarboxique utilisés comme pesticides
WO2012150208A1 (fr) 2011-05-04 2012-11-08 Bayer Cropscience Ag Utilisation d'esters d'alcools benzyliques substitués de l'acide cyclopropane carboxylique pour lutter contre des insectes résistants aux insecticides
CN105121411B (zh) 2013-04-15 2017-10-10 杜邦公司 杀真菌酰胺
CN103601671B (zh) * 2013-10-22 2016-08-17 上海泰坦科技股份有限公司 碘代三氟甲基吡啶的制备方法
WO2017049173A1 (fr) 2015-09-16 2017-03-23 Metacrine, Inc. Agonistes du récepteur x farnésoïde et leurs utilisations
RU2650610C1 (ru) 2017-02-28 2018-04-16 Васильевич Иващенко Александр Противовирусная композиция и способ ее применения
LT3609888T (lt) 2017-03-15 2025-11-10 Farnezoidinio x receptoriaus agonistai ir jų panaudojimas
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
ES2996837T3 (en) * 2017-08-07 2025-02-13 Amenis Biosciences Inc Novel anthranilic acid-based compound, and pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same
CN113056271B (zh) 2018-09-18 2024-10-29 奥加诺沃公司 法尼醇x受体激动剂及其用途
WO2020116296A1 (fr) * 2018-12-07 2020-06-11 ユニマテック株式会社 Composé de pyrimidine fluoré et procédé de production associé
CN111196785B (zh) * 2020-01-21 2021-08-31 成都新朝阳作物科学股份有限公司 三氮唑衍生物及其制备方法和用途
IL296532A (en) 2020-03-18 2022-11-01 Metacrine Inc Crystal forms of farnesoid x receptor agonist
WO2021188695A1 (fr) 2020-03-18 2021-09-23 Metacrine, Inc. Formulations d'un agoniste du récepteur farnésoïde x
US12448362B2 (en) 2020-05-19 2025-10-21 Unimatec Co., Ltd. Fluorine-containing pyrimidine compound and fluorine-containing pyrimidinone compound

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1507457A (en) 1974-11-12 1978-04-12 Agfa Gevaert Fixer compositions used in planographic printing
LU85544A1 (fr) 1984-09-19 1986-04-03 Cird Derives heterocycliques aromatiques,leur procede de preparation et leur application dans les domaines therapeutique et cosmetique
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
EP0946587A2 (fr) 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. Nouveaux composes amide
ES2234144T3 (es) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. Analogos de peptidos inhibidores de la hepatitis c.
WO1999007733A2 (fr) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Peptides inhibiteurs de l'hepatite c
DE19813802A1 (de) 1998-03-27 1999-11-11 Retro Tech Gmbh Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
WO2000006529A1 (fr) 1998-07-27 2000-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. Derives de dicetoacides utilises comme inhibiteurs de polymerases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
ES2546386T3 (es) 1999-07-20 2015-09-23 Dow Agrosciences, Llc Amidas aromáticas heterocíclicas fungicidas y sus composiciones, métodos de uso y preparación
PL205059B1 (pl) 1999-08-20 2010-03-31 Dow Agrosciences Llc Heterocykliczny amid aromatyczny, jego kompozycja grzybobójcza oraz sposób zwalczania lub zapobiegania zakażeniom grzybami
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
US6434489B1 (en) 2000-04-03 2002-08-13 Schering Corporation Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same
AR029903A1 (es) 2000-04-05 2003-07-23 Schering Corp Inhibidores macrociclicos de la ns3-serina proteasa, del virus de la hepatitis c, que comprenden partes p2 n-ciclicas, composiciones farmaceuticas y utilizacion de los mismos para la manufactura de un medicamento
CN101580536A (zh) 2000-04-19 2009-11-18 先灵公司 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
KR20030081297A (ko) 2000-07-21 2003-10-17 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
DK1385870T3 (da) 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
DE60119968T2 (de) 2000-11-20 2007-01-18 Bristol-Myers Squibb Co. Hepatitis c tripeptid inhibitoren
KR20030091946A (ko) 2000-12-12 2003-12-03 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 디아릴 펩티드
JP2004520839A (ja) 2001-03-08 2004-07-15 ベーリンガー インゲルハイム （カナダ） リミテッド Ｈｃｖのｒｎａ依存性ｒｎａポリメラーゼ（ｎｓ５ｂ）の阻害剤を同定するための分析法
EP1256628A3 (fr) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. ARN polymerase NS5B du virus de la hepatite C et mutants derivés de la polymerase
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003005025A1 (fr) * 2001-07-03 2003-01-16 Biovitrum Ab Procedes d'identification de composes modulant l'activite du ppar-gamma
CA2448737C (fr) 2001-07-20 2010-06-01 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de polymerase virale
EP2335700A1 (fr) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
WO2003026587A2 (fr) 2001-09-26 2003-04-03 Bristol-Myers Squibb Company Composes pour traiter le virus de l'hepatite c
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
GB0201179D0 (en) 2002-01-18 2002-03-06 Angeletti P Ist Richerche Bio Therapeutic agents
US6894072B2 (en) 2002-01-23 2005-05-17 Schering Corporation Compounds as NS3-serine protease inhibitors of hepatitis C virus
CA2369711A1 (fr) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Peptides macrocycliques qui agissent contre le virus de l'hepatite c
CA2369970A1 (fr) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
CA2370396A1 (fr) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Tri-peptides inhibiteur de l'hepatite c
MXPA04009672A (es) 2002-04-01 2004-11-12 Pfizer Inhibidores de la rna polimerasa dependiente del rna del virus de la hepatitis c, y las composiciones y los tratamientos que usan los mismos.
JP4312711B2 (ja) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー ヘテロ環式スルホンアミドｃ型肝炎ウイルス阻害剤
JP4271148B2 (ja) 2002-05-20 2009-06-03 ブリストル−マイヤーズ スクイブ カンパニー 置換シクロアルキルｐ１’ｃ型肝炎ウイルスインヒビター
WO2004032827A2 (fr) 2002-05-20 2004-04-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hepatite c
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
EP1556399A4 (fr) 2002-07-16 2007-09-26 Merck & Co Inc Derives de nucleosides utilises en tant qu'inhibiteurs de l'arn polymerase virale arn-dependante
US20040138109A1 (en) 2002-09-30 2004-07-15 Boehringer Ingelheim Pharmaceuticals, Inc. Potent inhibitor of HCV serine protease
EA010408B1 (ru) 2002-10-23 2008-08-29 Гленмарк Фармасьютикалс Лтд. Трициклические соединения для лечения воспалительных и аллергических нарушений, способы их приготовления и содержащие их фармацевтические составы
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
US20050159345A1 (en) 2002-10-29 2005-07-21 Boehringer Ingelheim International Gmbh Composition for the treatment of infection by Flaviviridae viruses
EP2361913A1 (fr) 2002-11-01 2011-08-31 Abbott Laboratories Agents anti-infectieux
US7902203B2 (en) 2002-11-01 2011-03-08 Abbott Laboratories, Inc. Anti-infective agents
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2515216A1 (fr) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la serine protease de l'hepatite c
CA2516016C (fr) 2003-03-05 2012-05-29 Boehringer Ingelheim International Gmbh Composes d'inhibition de l'hepatite c
US6908901B2 (en) 2003-03-05 2005-06-21 Boehringer Ingelheim International, Gmbh Hepatitis C inhibitor peptide analogs
JP4245377B2 (ja) 2003-03-07 2009-03-25 株式会社Ａｄｅｋａ 高弾性エポキシ樹脂組成物
GB0307891D0 (en) 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
KR101031825B1 (ko) 2003-04-18 2011-04-29 이난타 파마슈티칼스, 인코포레이티드 거대고리형 퀴녹살리닐 ｃ형 간염 세린 단백질분해효소억제제
DK1625154T3 (da) 2003-05-09 2014-02-24 Boehringer Ingelheim Int Hepatitis c virus ns5b-polymeraseinhibitor-bindende lomme
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
WO2004113365A2 (fr) 2003-06-05 2004-12-29 Enanta Pharmaceuticals, Inc. Inhibiteurs de la tripeptide hepatite c serine protease
GB0313250D0 (en) 2003-06-09 2003-07-16 Angeletti P Ist Richerche Bio Therapeutic agents
US7125845B2 (en) 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
WO2005014543A1 (fr) 2003-08-06 2005-02-17 Japan Tobacco Inc. Compose a cycle condense utilise comme inhibiteur de la polymerase du vhc
US7378414B2 (en) 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
WO2005019191A2 (fr) 2003-08-25 2005-03-03 Abbott Laboratories Agents anti-infectieux
US7449447B2 (en) 2003-08-26 2008-11-11 Schering Corporation Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
NZ546055A (en) 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
GB0321003D0 (en) 2003-09-09 2003-10-08 Angeletti P Ist Richerche Bio Compounds, compositions and uses
US7112601B2 (en) 2003-09-11 2006-09-26 Bristol-Myers Squibb Company Cycloalkyl heterocycles for treating hepatitis C virus
ES2361997T3 (es) 2003-09-22 2011-06-27 Boehringer Ingelheim International Gmbh Péptidos macrocíclicos activos contra el virus de la hepatitis c.
RU2006113880A (ru) 2003-09-26 2007-11-20 Шеринг Корпорейшн (US) Макроциклические ингибиторы сериновой протеиназы ns3 вируса гепатита с
GB0323845D0 (en) 2003-10-10 2003-11-12 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
WO2005037214A2 (fr) 2003-10-14 2005-04-28 Intermune, Inc. Acylsulfonamides et acides carboxyliques macrocycliques utilises en tant qu'inhibiteurs de la replication du virus de l'hepatite c
US20050119318A1 (en) 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005049622A1 (fr) 2003-11-19 2005-06-02 Japan Tobacco Inc. Compose heterocyclique fusionne a cinq branches et utilisation de celui-ci comme inhibiteur de la polymerase du vhc
MXPA06005683A (es) 2003-11-20 2006-12-14 Schering Corp Inhibidores despeptidizados de la proteasa ns3 del virus de la hepatitis c.
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
WO2005058821A1 (fr) 2003-12-11 2005-06-30 Schering Corporation Inhibiteurs de la protease serine ns3/ns4a du virus de l'hepatite c (hcv)
ATE495185T1 (de) 2004-01-21 2011-01-15 Boehringer Ingelheim Int Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
CN102911161A (zh) 2004-02-20 2013-02-06 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
JP4874227B2 (ja) 2004-02-27 2012-02-15 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼインヒビターとしての環状ｐ４’ｓを有する新規ケトアミド
EP1742914A1 (fr) 2004-02-27 2007-01-17 Schering Corporation Groupes cyclobutenedione contenant des composes servant d'inhibiteurs a la serine protease ns3 du virus de l'hepatite c
US7186747B2 (en) 2004-02-27 2007-03-06 Schering Corporation Compounds as inhibitors of hepatitis C virus NS3 serine protease
EP1737821B1 (fr) 2004-02-27 2009-08-05 Schering Corporation Composes de proline fusionnes a 3,4-(cyclopentyl) en tant qu'inhibiteurs de la protease serine ns3 du virus de l'hepatite c
CN1946691A (zh) 2004-02-27 2007-04-11 先灵公司 作为丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的化合物
DE602005021760D1 (de) 2004-02-27 2010-07-22 Schering Corp Schwefelverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
AU2005219859A1 (en) 2004-02-27 2005-09-15 Schering Corporation Inhibitors of hepatitis C virus NS3 protease
US7371743B2 (en) 2004-02-28 2008-05-13 Boehringer Ingelheim International Gmbh Carboxylic acid amides, the preparation thereof and their use as medicaments
AR049635A1 (es) 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
ES2328596T3 (es) 2004-05-20 2009-11-16 Schering Corporation Prolinas sustituidas como inhibidores de la serina proteasa del virus ns3 de la hepatitis c.
WO2005121132A1 (fr) 2004-06-11 2005-12-22 Shionogi & Co., Ltd. Composé hétérocyclique fondu ayant un effet anti-vhc
GB0413087D0 (en) 2004-06-11 2004-07-14 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2556669C (fr) 2004-06-28 2012-05-01 Boehringer Ingelheim International Gmbh Analogues peptidiques d'inhibiteurs de l'hepatite c
US20060004197A1 (en) 2004-07-02 2006-01-05 Thomas Thrash Sulfonamide-based compounds as protein tyrosine kinase inhibitors
PE20060569A1 (es) 2004-07-16 2006-06-22 Boehringer Ingelheim Int Compuestos de indol carbonilamino como inhibidores de la polimerasa ne5b del vhc
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
GB0416396D0 (en) 2004-07-22 2004-08-25 Angeletti P Ist Richerche Bio Therapeutic agents
US20060025480A1 (en) 2004-08-02 2006-02-02 Boehringer Ingelheim International Gmbh Benzoic acid derivatives as non nucleoside reverse transcriptase inhibitors
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
GB0419850D0 (en) 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
WO2006046039A2 (fr) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Derives d'indole tetracycliques utilises comme agents antiviraux
RU2398773C2 (ru) 2004-11-02 2010-09-10 Баниу Фармасьютикал Ко., Лтд. Арилоксизамещенное производное бензимидазола
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
WO2006093801A1 (fr) 2005-02-25 2006-09-08 Abbott Laboratories Derives de thiadiazine utiles en tant qu’agents anti-infectieux
CA2600886A1 (fr) 2005-03-08 2006-09-14 Biota Scientific Management Pty Ltd. Nucleosides bicycliques et nucleotides servant d'agents therapeutiques
AU2006242475B2 (en) 2005-05-02 2011-07-07 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
GB0509326D0 (en) 2005-05-09 2005-06-15 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2006119646A1 (fr) 2005-05-13 2006-11-16 Virochem Pharma Inc. Composés et méthodes pour le traitement prophylactique ou thérapeutique d'infections par un flavivirus
TWI387603B (zh) 2005-07-20 2013-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
JP2009501732A (ja) 2005-07-20 2009-01-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
WO2007014922A1 (fr) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Inhibiteurs macrocycliques du virus de l'hépatite c
BRPI0614205A2 (pt) 2005-08-01 2016-11-22 Merck & Co Inc composto, composição farmacêutica, e, uso de composto
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007028789A1 (fr) 2005-09-07 2007-03-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Dérivés de quinazoline en tant qu'agents antiviraux
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
BRPI0520554A2 (pt) 2005-09-19 2009-06-13 Arrow Therapeutics Ltd uso de uma benzodiazepina ou um sal farmaceuticamente aceitável do mesmo, método para tratar ou prevenir uma infecção por hcv em um paciente, derivado de benzodiazepina ou um sal famaceuticamente aceitável do mesmo, e, composição farmacêutica
WO2007039146A1 (fr) 2005-09-23 2007-04-12 Smithkline Beecham Corporation Derives de 4-carboxy pyrazole utilises en tant qu'agents antiviraux
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
ITRM20050611A1 (it) 2005-12-06 2007-06-07 Angeletti P Ist Richerche Bio Derivati azanucleosidici ad attivita' antivirale.
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2007092000A1 (fr) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibiteurs de réplication du vhc
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
EP1987050A2 (fr) 2006-02-14 2008-11-05 Merck & Co., Inc. Phosphoramidates d'aryle nucleosidiques pour le traitement d'infections ribovirales dependantes de l'arn
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456167B2 (en) 2006-05-25 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
JP2010500978A (ja) 2006-08-17 2010-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
AU2008277440A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections
CA2693997C (fr) 2007-08-03 2013-01-15 Pierre L. Beaulieu Inhibiteurs de polymerase virale
WO2009018656A1 (fr) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Inhibiteurs de polymerase virale
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
JP5421925B2 (ja) 2007-12-19 2014-02-19 ジェネンテック， インコーポレイテッド ５−アニリノイミダゾピリジン及び使用の方法
TWI432421B (zh) 2007-12-19 2014-04-01 Du Pont 製備２－胺基－５－氰基苯甲酸衍生物之方法
EP2235005A2 (fr) 2007-12-19 2010-10-06 Basf Se Azolylméthyloxiranes, leur utilisation et agents les contenant
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
PE20091524A1 (es) 2007-12-19 2009-09-25 Palau Pharma Sa Derivados de 2-aminopirimidina
WO2009077497A2 (fr) 2007-12-19 2009-06-25 Basf Se Azolylméthyloxiranes, utilisation de ceux-ci et agents contenant ceux-ci
JP2011507815A (ja) 2007-12-19 2011-03-10 ビーエーエスエフ ソシエタス・ヨーロピア アゾリルメチルオキシラン類、それらの使用およびそれらを含む組成物
EP2234488A2 (fr) 2007-12-19 2010-10-06 Basf Se Azolylméthyloxiranes, leur utilisation et agents les contenant
UY31544A1 (es) 2007-12-19 2009-07-17 Compuestos que potencian el receptor de ampa y usos de los mismos en medicina
EP2350039A4 (fr) 2008-10-03 2012-10-10 Boehringer Ingelheim Int Inhibiteurs de la polymérase virale

Also Published As

Publication number Publication date
AU2008338273B2 (en) 2014-10-02
ZA201002638B (en) 2011-04-28
CA2708324A1 (fr) 2009-06-25
JP5623289B2 (ja) 2014-11-12
US20120214783A1 (en) 2012-08-23
PE20091103A1 (es) 2009-08-25
UY31538A1 (es) 2009-08-03
AR069832A1 (es) 2010-02-24
US8476257B2 (en) 2013-07-02
EA201000948A1 (ru) 2011-02-28
CN103483251A (zh) 2014-01-01
EP2234977A1 (fr) 2010-10-06
US8912182B2 (en) 2014-12-16
BRPI0821342A2 (pt) 2019-09-24
US20110021486A1 (en) 2011-01-27
TN2010000291A1 (fr) 2011-11-11
ECSP10010260A (es) 2010-07-30
JP2011506491A (ja) 2011-03-03
US8541402B2 (en) 2013-09-24
IL205064A0 (en) 2010-11-30
US20130331391A1 (en) 2013-12-12
NZ585370A (en) 2012-09-28
CL2008003819A1 (es) 2010-02-12
TW200927106A (en) 2009-07-01
EP2234977A4 (fr) 2011-04-13
CO6231024A2 (es) 2010-12-20
KR20100098534A (ko) 2010-09-07
CA2708324C (fr) 2013-03-05
MX2010006313A (es) 2010-06-25
CN101903351A (zh) 2010-12-01
CN101903351B (zh) 2014-09-10
AU2008338273A1 (en) 2009-06-25
PE20130157A1 (es) 2013-02-27
WO2009076747A1 (fr) 2009-06-25

Similar Documents

Publication Publication Date Title
MA32006B1 (fr) Inhibiteurs de polymerase virale
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
TW200745151A (en) Antiviral nucleosides
EA200601457A1 (ru) Ингибиторы вирусной полимеразы
EA200900676A1 (ru) Ингибиторы вируса гепатита с
MA30893B1 (fr) Inhibiteurs de la protease ns3 du vhc
TW200626559A (en) Anilino-pyrimidine analogs
CY1111423T1 (el) Αναστολεις ns5b hcv
MA29135B1 (fr) Potentialisateurs de recepteurs du glutamate
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
EA200901241A1 (ru) Соединения для лечения гепатита с
EA200701822A1 (ru) Пиразолилкарбоксанилиды
TW200833678A (en) HCV protease inhibitorscross reference
MX2008012404A (es) Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
MX2012008443A (es) Nucleosidos antiviricos.
WO2006027628A3 (fr) Derives de naphtalimide en tant qu'agents antiviraux
MA31759B1 (fr) Compose amide
CL2004001161A1 (es) Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
MA33360B1 (fr) Composés antiviraux hétérocycliques
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
WO2007084435A8 (fr) Procedes de traitement de l'hepatite c
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
WO2012019299A9 (fr) Composés inhibiteurs de l'hépatite c
EA200802074A1 (ru) Способ получения бисфуранового спирта, соединения, соль, фармацевтическая композиция на ее основе, способ для лечения или профилактики ретровирусных инфекций с ее помощью и способ ингибирования вич протеазы с ее помощью
ATE432922T1 (de) Substituierte 5-carboxyamidpyrazoles und ä1,2, 4ütriazole als viruzide